Current Problems in Cancer
Volume 30, Issue 1 , Pages 7-32 , January 2006

Targeting VEGF in Cancer Therapy

  • Erin A. Donovan, MD
    • ,
  • Shivaani Kummar, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Shivaani Kummar, MD, Senior Staff Clinician, Medical Oncology Branch, National Cancer Institute, 8901 Wisconsin Avenue, Bldg. 8/Rm. 5101, Bethesda, MD 20889, USA.

References 

  1. Ferrara N . Vascular endothelial growth factor as a target for anticancer therapy . Oncologist . 2004;9:2–10
  2. Hicklin D , Ellis L . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis . J Clin Oncol . 2005;23:1011–1027
  3. Parikh A , Ellis L . The vascular endothelial growth factor family and its receptors . Hematol Oncol Clin N Am . 2004;18:951–971
  4. Xie K , Wei D , Shi Q , Huang S . Constitutive and inducible expression and regulation of vascular endothelial growth factor . Cytokine Growth Factor Rev . 2004;15:297–324
  5. DiSalvo J , Conn G , Trivedi P , et al.   Purification and characterization of a naturally occurring vascular endothelial growth factor-placenta growth factor heterodimer . J Biol Chem . 1995;270:7717–7723
  6. Ton N , Jayson G . Resistance to anti-VEGF agents . Curr Pharmaceut Des . 2004;10:51–64
  7. Ferrara N , Hillan K , Gerber H-P , Novotny W . Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer . Nat Rev Drug Discov . 2004;3:391–400
  8. Holash J , Davis S , Papadopoulos N , et al.   VEGF-Trap (a VEGF blocker with potent antitumor effects) . Proc Natl Acad Sci USA . 2002;99:11393–11398
  9. Dupont J , Schwartz L , Koutcher J , et al.   Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies . Proc Am Soc Clin Oncol . 2004;3009a
  10. Konner J , Dupont J . Use of soluble recombinant decoy receptor vascular endothelial growth factor Trap (VEGF Trap) to inhibit vascular endothelial growth factor activity . Clin Colorectal Cancer . 2004;4:S81–S85
  11. Dupont J , Rothenberg M , Spriggs D , et al.   Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors . Proc Am Soc Clin Oncol . 2005;3029a
  12. Morgan B , Thomas A , Drevs J , et al.   Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases (results from two phase I studies) . J Clin Oncol . 2003;21:3955–3964
  13. Drevs J , Mross K , Medinger M , et al.   Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastases . Proc Am Soc Clin Oncol . 2003;1142a
  14. Thomas A , Morgan B , Horsfield M , et al.   Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer . J Clin Oncol . 2005;23:4162–4171
  15. Ryan A , Wedge S . ZD6474 (a novel inhibitor of VEGFR and EGFR tyrosine kinase activity) . Br J Cancer . 2005;92:S6–S13
  16. Hurwitz H , Holden S , Eckhardt S , et al.   Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors . Proc Am Soc Clin Oncol . 2002;325a
  17. Heymach J . ZD6474 (clinical experience to date) . Br J Cancer . 2005;92:S14–S20
  18. Wilhelm S , Carter C , Tang L , et al.   BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis . Cancer Res . 2004;64:7099–7109
  19. Strumberg D , Richly H , Hilger R , et al.   Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors . J Clin Oncol . 2005;23:965–972
  20. O’Farrell A-M , Abrams T , Yuen H , et al.   SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo . Blood . 2003;101:3597–3605
  21. Mendel D , Laird A , Xin X , et al.   In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors (determination of a pharmacokinetic/pharmacodynamic relationship) . Clin Cancer Res . 2003;9:327–337
  22. Rosen L , Mulay M , Long J , et al.   Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors . Proc Am Soc Clin Oncol . 2003;765a
  23. Traxler P , Allegrini P , Brandt R , et al.   AEE788 (A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity) . Cancer Res . 2004;64:4931–4941
  24. Martinelli E , Takimoto C , vanOosterom A , et al.   AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases (preliminary phase I results) . Proc Am Soc Clin Oncol . 2005;3039a
  25. Baselga J , Rojo F , Dumez H , et al.   Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases (a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen) . Proc Am Soc Clin Oncol . 2005;3028a
  26. Levine A , Quinn D , Gorospe G , et al.   Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies . Proc Am Soc Clin Oncol . 2004;3008a
  27. Takebayashi Y , Aklyama S , Yamada K , et al.   Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma . Cancer . 1996;78:226–231
  28. Takahashi Y , Kitadai Y , Bucana C , et al.   Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer . Cancer Res . 1995;55:3964–3968
  29. Lee J-C , Chow N-H , Wang S-T , Huang S-M . Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients . Eur J Cancer . 2000;36:748–753
  30. Ellis L . Angiogenesis and its role in colorectal tumor and metastasis formation . Semin Oncol . 2004;31:3–9
  31. Fan F , Wey J , McCarty M , et al.   Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells . Oncogene . 2005;24:2647–2653
  32. Kabbinavar F , Hurwitz H , Fehrenbacher L , et al.   Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer . J Clin Oncol . 2003;21:60–65
  33. Petrelli N , Douglass H , Herrera L , et al.  GI Tumor Study Group   Modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma (A prospective randomized phase III trial) . J Clin Oncol . 1989;7:1419–1426
  34. Saltz L , Kanowitz J , Kerneny N , et al.   Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors . J Clin Oncol . 1996;14:2959–2967
  35. Hurwitz H , Fehrenbacher L , Novotny W , et al.   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J Med . 2004;350:2335–2342
  36. Hurwitz H , Fehrenbacher L , Hainsworth J , et al.   Bevacizumab in combination with fluorouracil and leucovorin (An active regimen for first-line metastatic colorectal cancer) . J Clin Oncol . 2005;23:3502–3508
  37. Kabbinavar F , Schulz J , McCleod M , et al.   Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer (Results of a randomized phase II trial) . J Clin Oncol . 2005;23:3697–3705
  38. Kabbinavar F , Hambleton J , Mass R , et al.   Combined analysis of efficacy (The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer) . J Clin Oncol . 2005;23:3706–3712
  39. DeGramont A , Figer A , Seymour M , et al.   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer . J Clin Oncol . 2000;18:2938–2947
  40. Giantonio B , Catalano P , Meropol N , et al.   High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer (Results from the Eastern Cooperative Oncology Group (ECOG) study E3200) . Proc Am Soc Clin Oncol . 2005;2a
  41. Reddy G . The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer (Interim data from the ECOG 3200 trial) . Clin Colorectal Cancer . 2005;4:300–301
  42. Chen H , Mooney M , Boron M , et al.   Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies (An NCI Treatment Referral Center trial (TRC-0301)) . Proc Am Soc Clin Oncol . 2004;3515a
  43. Saltz L , Lenz H , Hochster H , et al.   Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer . Proc Am Soc Clin Oncol . 2005;3508a
  44. Saltz L , Lenz H , Kindler H , et al.   Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer . ASCO Gastrointest Cancer Symp . 2005;169b
  45. Klem J . Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor, in colorectal cancer . Clin Colorectal Cancer . 2003;3:147–149
  46. Tyagi P . Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer (Preliminary results from the CONFIRM-1 trial) . Clin Colorectal Cancer . 2005;5:24–26
  47. Andre T , Louvet C , Maindrault-Goebel F , et al.   CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR . Eur J Cancer . 1999;35:1343–1347
  48. Trarbach T , Thomas A , Bartel C , et al.   Preliminary phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer . Eur J Cancer Suppl . 2003;1:S91
  49. Steward W , Thomas A , Morgan B , et al.   Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer . Proc Am Soc Clin Oncol . 2004;3556a
  50. Hecht J , Trarbach T , Jaeger E , et al.   A randomized double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) . Proc Am Soc Clin Oncol . 2005;LBA3
  51. Bukowski R . Cytokine therapy for metastatic renal cell carcinoma . Semin Urol Oncol . 2001;19:148–154
  52. Rini B , Small E . Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma . J Clin Oncol . 2005;23:1028–1043
  53. Crossey P , Foster K , Richards F , et al.   Molecular genetic investigations of the mechanism of tumorigenesis in von Hippel-Lindau disease (analysis of allele loss in VHL tumors) . Hum Genet . 1994;93:53–58
  54. Gnarra J , Tory K , Weng Y , et al.   Mutations of the VHL tumour suppressor gene in renal carcinoma . Nat Genet . 1994;7:85–90
  55. Shuin T , Kondo K , Torigoe S , et al.   Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas . Cancer Res . 1994;54:2852–2855
  56. Gallou C , Joly D , Mejean A , et al.   Mutations of the VHL gene in sporadic renal cell carcinoma (Definition of a risk factor for VHL patients to develop an RCC) . Hum Mutat . 1999;13:464–475
  57. Maxwell P , Wiesener M , Chang G , et al.   The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis . Nature . 1999;399:271–275
  58. Cockman M , Masson N , Mole D , et al.   Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein . J Biol Chem . 2000;275:25733–25741
  59. Iliopoulos O , Levy A , Jiang C , et al.   Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein . Proc Natl Acad Sci USA . 1996;93:10595–10599
  60. Gnarra J , Zhou S , Merrill M , et al.   Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene . Proc Natl Acad Sci USA . 1996;93:10589–10594
  61. Na X , Guan W , Ryan C , et al.   Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1α expression in renal cell carcinomas . J Urol . 2003;170:588–592
  62. Turner K , Moore J , Jones A , et al.   Expression of hypoxia-inducible factors in human renal cancer (Relationship to angiogenesis and to the von Hippel-Lindau gene mutation) . Cancer Res . 2002;62:2957–2961
  63. Yang J , Haworth L , Sherry R , et al.   A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer . N Engl J Med . 2003;349:427–434
  64. Elaraj D , White D , Steinberg S , et al.   A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma . J Immunother . 2004;27:259–264
  65. Spigel D , Hainsworth J , Sosman J , et al.   Bevacizumab and erlotonib in the treatment of patients with metastatic renal cell carcinoma (RCC) (Update of a phase II multicenter trial) . Proc Am Soc Clin Oncol . 2005;4540a
  66. Rini B , Halabi S , Taylor J , et al.   Cancer and Leukemia Group B 90206 (A randomized phase III trial of interferon-α or interferon-α plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma) . Clin Cancer Res . 2004;10:2584–2586
  67. George D , Michaelson D , Oh W , et al.   Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma . Proc Am Soc Clin Oncol . 2003;1548a
  68. Ahmad T , Eisen T . Kinase inhibition with BAY 43-9006 in renal cell carcinoma . Clin Cancer Res . 2004;10:6388s–6392s
  69. O’Dwyer P , Rosen M , Gallagher M , et al.   Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma Proc Am Soc Clin Oncol . 2005;3005a
  70. Ratain M , Flaherty K , Stadler W , et al.   Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) . Proc Am Soc Clin Oncol . 2004;4501a
  71. Herbst R , Onn A , Sandler A . Angiogenesis and lung cancer (Prognostic and therapeutic implications) . J Clin Oncol . 2005;23:3243–3256
  72. Han H , Silverman J , Santucci T , et al.   Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis . Ann Surg Oncol . 2001;8:72–79
  73. Fontanini G , Faviana P , Lucchi M , et al.   A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma . Br J Cancer . 2002;86:558–563
  74. Koukourakis M , Giatromanolaki A , Thorpe P , et al.   Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer . Cancer Res . 2000;60:3088–3095
  75. Johnson D , Fehrenbacher L , Novotny W , et al.   Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer . J Clin Oncol . 2004;22:2184–2191
  76. Herbst R , Johnson D , Mininberg E , et al.   Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotonib for patients with recurrent non-small-cell lung cancer . J Clin Oncol . 2005;23:2544–2555
  77. Lee D . Multitargeted kinase inhibitors in non-small-cell lung cancer . Oncol Brief . 2005;3:1–3
  78. Raefsky E , Spigel D , Greco F , et al.   Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC) (a phase II trial of the Minnie Pearl Cancer Research Network) . Proc Am Soc Clin Oncol . 2005;7050a
  79. Heymach J , Dong R-P , Dimery I , et al.   ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC (Results of the run-in phase of a two-part, randomized phase II study) . Proc Am Soc Clin Oncol . 2004;3051a
  80. Heymach J , Johnson B , Rowbottom J , et al.   A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel in patients with NSCLC . Proc Am Soc Clin Oncol . 2005;3023a
  81. Herbst R , Johnson B , Rowbottom J , et al.   ZD6474 plus docetaxel in patients with previously treated NSCLC (Results of a randomized, placebo-controlled phase II trial) . Lung Cancer . 2005;49:S35–S36
  82. Cohen R , Simon G , Langer C , et al.   Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC) . Proc Am Soc Clin Oncol . 2004;3014a
  83. Weidner N , Semple J , Welch W , Folkman J . Tumor angiogenesis and metastasis –correlation in invasive breast carcinoma . N Engl J Med . 1991;324:1–8
  84. Schneider B , Miller K . Angiogenesis of breast cancer . J Clin Oncol . 2005;23:1782–1790
  85. Gasparini G , Toi M , Gion M , et al.   Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma . J Natl Cancer Inst . 1997;89:139–147
  86. Ragaz J , Miller K , Badve S , et al.   Adverse association of expressed vascular endothelial growth factor (VEGF), Her2, Cox2, uPA and EMSY with long-term outcome of stage I-III breast cancer (BrCa). Results from the British Columbia Tissue Microarray Project . Proc Am Soc Clin Oncol . 2004;524a
  87. Cobleigh M , Langmuir V , Sledge G , et al.   A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer . Semin Oncol . 2003;30:117–124
  88. Burstein H , Parker L , Savoie J , et al.   Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer . Breast Cancer Res Treat . 2002;76:S115
  89. Ramaswamy B , Rhoades C , Kendra K , et al.   CTEP-sponsored phase II trial of bevacizumab (Avastin®) in combination with docetaxel (Taxotere) in metastatic breast cancer . Breast Cancer Res Treat . 2003;82:S50
  90. Pegram M , Yeon C , Ku N , et al.   Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF) . Breast Cancer Res Treat . 2004;88:S124
  91. Dickler M , Rugo H , Caravelli J , et al.   Phase II trial of erlotonib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC) . Proc Am Soc Clin Oncol . 2004;2001a
  92. Traina T , Dickler M , Caravelli J , et al.   A feasibility study of an aromatase inhibitor (AI), letrozole (L), and the antibody to vascular endothelial growth factor (VEGF), bevacizumab (B), in patients with hormone receptor-positive metastatic breast cancer (MBC) . Proc Am Soc Clin Oncol . 2005;796a
  93. Overmoyer B , Silverman P , Leeming R , et al.   Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer . Breast Cancer Res Treat . 2004;88:S106
  94. Wedam S , Low J , Yang X , et al.   A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer . Proc Am Soc Clin Oncol . 2004;578a
  95. Miller K , Rugo H , Cobleigh M , et al.   Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane . Breast Cancer Res Treat . 2002;76:S37
  96. Hillan K , Koeppen H , Tobin P , et al.   The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC) . Proc Am Soc Clin Oncol . 2003;766a
  97. Miller K , Trigo J , Wheeler C , et al.   A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer . Clin Cancer Res . 2005;11:3369–3376

PII: S0147-0272(05)00088-7

doi: 10.1016/j.currproblcancer.2005.11.001

Current Problems in Cancer
Volume 30, Issue 1 , Pages 7-32 , January 2006

Article Tools

* Image Usage & Resolution